Relationship between expression of Pad1 homologue and multidrug resistance of idiopathic nephrotic syndrome.
BACKGROUND
Multidrug resistance is an occasionally seen phenomenon in children with idiopathic nephrotic syndrome (INS), but the mechanism of multidrug resistance is not clear as yet. The purpose of the present study was to investigated whether expression of Pad1 homologue (POH1) plays a role in the onset of multidrug resistance of INS.


METHODS
Comparison was done of the mRNA level of POH1 on real-time quantitative polymerase chain reaction in peripheral blood mononuclear cells among children with multidrug-resistant INS, children with steroid-sensitive INS and healthy controls.


RESULTS
The POH1 mRNA level of the onset INS group (5852.3 +/- 2676.4 copies/microg) was significantly lower than that of the control group (10 877.1 +/- 2386.6 copies/microg; P < 0.05). The POH1 mRNA level of the onset INS group with multidrug resistance was not significantly higher than that of the onset INS group without multidrug-resistance before treatment (6977.1 +/- 6312.3 copies/microg vs 5281.3 +/- 1926.7 copies/microg; P > 0.05), but significantly higher than that of the onset INS group without multidrug resistance after treatment (436 579.6 +/- 99 727.4 copies/microg vs 38 438.2 +/- 16 772.5 copies/microg; P < 0.001). The POH1 mRNA level of non-onset multidrug-resistant INS group (337 446.4 +/- 107 423.5 copies/microg) after treatment was not significantly higher than that of the onset INS group with multidrug resistance after treatment (436 579.6 +/- 99 727.4 copies/microg; P > 0.05), but was significantly higher than that of the onset INS group without multidrug resistance after treatment (38 438.2 +/- 16 772.5 copies/microg; P < 0.001).


CONCLUSIONS
Disorder of POH1 expression is involved in the onset of INS, and confers multidrug resistance in children with INS.
Divisions of Pediatric Nephrology, Shenzhen Children's Hospital, Guangdong, China. mzx7321@sina.com
Zuxiang
Z
Ma
Xiaojie
X
Gao
Weiling
W
Zhao
Yongbai
Y
Li
Changgang
C
Li
Chengrong
C
Li
D000293:Adolescent; D016022:Case-Control Studies; D002648:Child; D002675:Child, Preschool; D018432:Drug Resistance, Multiple / Q000235:genetics*; D005260:Female; D015870:Gene Expression; D019450:Genes, MDR / Q000235:genetics; D005938:Glucocorticoids / Q000008:administration & dosage*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D007223:Infant; D008297:Male; D009404:Nephrotic Syndrome / Q000188:drug therapy*; D046988:Proteasome Endopeptidase Complex / Q000235:genetics*; D015534:Trans-Activators / Q000235:genetics*
D005938:Glucocorticoids; D007166:Immunosuppressive Agents; C109285:PSMD14 protein, human; D015534:Trans-Activators; D046988:Proteasome Endopeptidase Complex